Arcadia Biosciences Company Insiders
| RKDA Stock | USD 2.03 0.09 4.25% |
Arcadia Biosciences employs about 21 people. The company is managed by 31 executives with a total tenure of roughly 176 years, averaging almost 5.0 years of service per executive, having 0.68 employees per reported executive. Analysis of Arcadia Biosciences' management performance can provide insight into the company performance.
| Rajendra Ketkar CEO President CEO, Director |
| Eric Rey CEO CEO and President and Director (Leave of Absence) |
Arcadia |
Arcadia Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.345) % which means that it has lost $0.345 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7836) %, meaning that it created substantial loss on money invested by shareholders. Arcadia Biosciences' management efficiency ratios could be used to measure how well Arcadia Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Arcadia Biosciences Workforce Comparison
Arcadia Biosciences is rated below average in number of employees category among related companies. The total workforce of Consumer Staples industry is at this time estimated at about 8,399. Arcadia Biosciences adds roughly 21.0 in number of employees claiming only tiny portion of stocks in Consumer Staples industry.
The company has Profit Margin (PM) of (2.62) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.4) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.4. Arcadia Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcadia Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcadia Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arcadia Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kevin Comcowich over a month ago Acquisition by Kevin Comcowich of 21320 shares of Arcadia Biosciences at 3.69 subject to Rule 16b-3 | ||
Thomas Schaefer over two months ago Purchase by Thomas Schaefer of 700 shares of Arcadia Biosciences | ||
Schaefer Thomas J over six months ago Purchase by Schaefer Thomas J of 649 shares of Arcadia Biosciences | ||
Gregory Waller over six months ago Acquisition by Gregory Waller of 937 shares of Arcadia Biosciences subject to Rule 16b-3 | ||
Schaefer Thomas J over a year ago Purchase by Schaefer Thomas J of 700 shares of Arcadia Biosciences |
Arcadia Biosciences Notable Stakeholders
An Arcadia Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arcadia Biosciences often face trade-offs trying to please all of them. Arcadia Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arcadia Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Rajendra Ketkar | President CEO, Director | Profile | |
| Eric Rey | CEO and President and Director (Leave of Absence) | Profile | |
| Stanley Jacot | CEO President | Profile | |
| Darby Shupp | Chairman of the Board | Profile | |
| Mark Wong | Acting CEO, Acting President, Director and Chairman of Compensation Committee | Profile | |
| Donald Emlay | Vice President - Regulatory Affairs and Compliance | Profile | |
| Zhongjin Lu | Vice President - Product Development | Profile | |
| Roger Salameh | Vice President - Business Development | Profile | |
| Steven Brandwein | Interim CFO | Profile | |
| Thomas Schaefer | CFO Secretary | Profile | |
| Uday Garg | Independent Director | Profile | |
| Peter Gajdos | Director | Profile | |
| Gregory Waller | Director | Profile | |
| George Gosbee | Director Nominee | Profile | |
| Kevin Comcowich | Independent Director | Profile | |
| Albert Bolles | Director | Profile | |
| Lilian Murray | Director | Profile | |
| Jamie Bechtel | Director | Profile | |
| Matthew Ankrum | Director Nominee | Profile | |
| Amy Yoder | Director | Profile | |
| Rajiv Shah | Director Nominee | Profile | |
| James Reis | Independent Director | Profile | |
| Wendy Neal | Chief Legal Officer, VP and Secretary | Profile | |
| Tracy Baker | Senior Operations | Profile | |
| Vic Knauf | Chief Scientific Officer | Profile | |
| Pamela Haley | CFO Sec | Profile | |
| Laura Pitlik | Chief Officer | Profile | |
| Belinda Yao | VP Operations | Profile | |
| Sarah Reiter | Chief Commercial Officer | Profile | |
| Kevin Hodges | VP Operations | Profile | |
| Brian Schaffer | Senior Sales | Profile |
About Arcadia Biosciences Management Performance
The success or failure of an entity such as Arcadia Biosciences often depends on how effective the management is. Arcadia Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arcadia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arcadia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. The company was incorporated in 2002 and is headquartered in Davis, California. Arcadia Bio operates under Agricultural Inputs classification in the United States and is traded on NASDAQ Exchange. It employs 58 people.
The data published in Arcadia Biosciences' official financial statements usually reflect Arcadia Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Arcadia Biosciences. For example, before you start analyzing numbers published by Arcadia accountants, it's critical to develop an understanding of what Arcadia Biosciences' liquidity, profitability, and earnings quality are in the context of the Food Products space in which it operates.
Please note, the presentation of Arcadia Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arcadia Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Arcadia Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arcadia Biosciences. Please utilize our Beneish M Score to check the likelihood of Arcadia Biosciences' management manipulating its earnings.
Arcadia Biosciences Workforce Analysis
Traditionally, organizations such as Arcadia Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arcadia Biosciences within its industry.Arcadia Biosciences Manpower Efficiency
Return on Arcadia Biosciences Manpower
| Revenue Per Employee | 253.8K | |
| Revenue Per Executive | 171.9K | |
| Net Loss Per Employee | 626.7K | |
| Net Loss Per Executive | 424.5K | |
| Working Capital Per Employee | 542K | |
| Working Capital Per Executive | 367.2K |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.Note that the Arcadia Biosciences information on this page should be used as a complementary analysis to other Arcadia Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Arcadia Stock analysis
When running Arcadia Biosciences' price analysis, check to measure Arcadia Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcadia Biosciences is operating at the current time. Most of Arcadia Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcadia Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcadia Biosciences' price. Additionally, you may evaluate how the addition of Arcadia Biosciences to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Arcadia Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.